Lv2
110 积分 2022-01-04 加入
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
25天前
已完结
Treatment strategies for patients with diffuse large B-cell lymphoma
26天前
已完结
Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
26天前
已完结
Improved growth with growth hormone therapy in a child with glycogen storage disease Ib
30天前
已完结
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
1个月前
已完结
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
3个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
3个月前
已完结
Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
3个月前
已完结
Clinical Characteristics of Pathogenic <i>ACAN</i> Variants and 3-Year Response to Growth Hormone Treatment: Real-World Data
3个月前
已完结
The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities
4个月前
已完结
皖公网安备34019202002308
